Tranexamic acid + Standard of Care — Competitive Intelligence Brief

Tranexamic acid + Standard of Care (Tranexamic acid + Standard of Care) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic agent. Area: Hematology / Surgery / Trauma.

marketed Antifibrinolytic agent Plasminogen / Plasmin Hematology / Surgery / Trauma Small molecule

Target snapshot

Tranexamic acid + Standard of Care (Tranexamic acid + Standard of Care) — Pfizer. Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, reducing blood loss in surgical and trauma settings when combined with standard care.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tranexamic acid + Standard of Care TARGET	Tranexamic acid + Standard of Care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid / Sodium chloride	Tranexamic Acid / Sodium chloride	University Hospital, Bordeaux	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Injectable Solution	Tranexamic Acid Injectable Solution	Mount Sinai Hospital, Canada	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic acid intravenous administration	Tranexamic acid intravenous administration	Dr. Lutfi Kirdar Kartal Training and Research Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid plus standard of care	Tranexamic Acid plus standard of care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
tranexamic acid Oral-Short Arm	tranexamic acid Oral-Short Arm	Rush University Medical Center	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Irrigation	Tranexamic Acid Irrigation	University of Wisconsin, Madison	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic agent class)

1. Montefiore Medical Center · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Hamilton Health Sciences Corporation · 2 drugs in this class
4. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
5. Henry Ford Health System · 1 drug in this class
6. Massachusetts General Hospital · 1 drug in this class
7. NYU Langone Health · 1 drug in this class
8. Mount Sinai Hospital, Canada · 1 drug in this class
9. Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 drug in this class
10. Carlos A Acosta-Olivo · 1 drug in this class